Effects of Evantumumab/Carestream on the Immune System

Amivantamab is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC). It is a bispecific monoclonal antibody that targets both EGFR (epidermal growth factor receptor) and c-MET (fibroblast growth factor receptor). These two targets play key roles in many cancers, especially lung cancer cells. By binding to these targets, evantumumab is able to exert anti-tumor effects while also affecting the immune system.

Evantumumab enhances the immune system's recognition and attack of tumor cells by regulating the mechanism of the immune system. First, it can stimulate antibody-dependent cell-mediated cytotoxicity (ADCC), which kills tumor cells by activating immune cells (such as natural killer cells, NK cells). In addition, evantumumab also inhibits the proliferation and metastasis of cancer cells by blocking the signaling pathways of EGFR and c-MET.

The role of evantumumab is not limited to direct attack on tumor cells. It can also enhance the anti-tumor ability of the patient's immune system by adjusting the immune microenvironment. For example, by enhancing the activity ofT cells, it helps the immune system identify and destroy cancer cells more effectively. In some cases, evantumumab's effects on the immune system may cause immune-related side effects, including rash, allergic reactions, or more severe immune-mediated inflammatory reactions.

Although evantumumab inhibits tumors by enhancing the function of the immune system, its immunomodulatory effects may lead to adverse effects, especially when the immune system is overactivated. Therefore, immune responses need to be closely monitored during treatment and appropriate measures taken to avoid excessive immune responses. By dual-targeting EGFR and c-MET, evantumumab not only plays a direct anti-tumor role, but also enhances the anti-tumor ability of the patient's immune system by regulating immune responses.

Reference materials:https://www.rybrevant.com/